New antiretrovirals in the pipeline could be part of twice-yearly HIV treatment

aidsmap news story

Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could be components of future long-acting HIV treatment regimens, according to study results presented at CROI 2026.

Pharmacokinetic data showed that ViiV Healthcare’s investigational capsid inhibitor VH-499, ViiV’s next generation integrase inhibitor VH-184 and Gilead Sciences’ pipeline integrase inhibitor GS-3242 could potentially be administered by injection just twice a year. All three drugs were safe and generally well tolerated, and phase II studies are expected to start this year.

Read the full news story here.View all aidsmap reports from CROI 2026